Anixa Biosciences Inc.

4.23+0.0800+1.93%Vol 61.60K1Y Perf 90.50%
Jun 15th, 2021 16:00 DELAYED
BID4.19 ASK4.23
Open4.17 Previous Close4.15
Pre-Market- After-Market-
 - -  - -%
Target Price
9.50 
Analyst Rating
Strong Buy 1.00
Potential %
124.59 
Finscreener Ranking
★★★★★     60.62
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
★★★+     53.72
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
★★★+     56.17
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Market Cap126.69M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
39.59 
Earnings Date
15th Jun 2021

Today's Price Range

4.054.24

52W Range

1.708.09

5 Year PE Ratio Range

-10.40-7.20

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
0.71%
1 Month
13.71%
3 Months
-31.99%
6 Months
60.23%
1 Year
90.50%
3 Years
27.03%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ANIX4.230.08001.93
AAPL129.64-0.8400-0.64
GOOG2 520.66-6.3800-0.25
MSFT258.36-1.5300-0.59
XOM64.332.26003.64
WFC45.460.31000.69
JNJ164.49-0.8800-0.53
FB336.75-0.0200-0.01
GE13.540.07000.52
JPM155.18-2.3900-1.52
Financial StrengthValueIndustryS&P 500US Markets
9.20
9.50
0.00
0.00
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
24.90
-1 869.60
-1 854.50
-2 757.80
-
RevenueValueIndustryS&P 500US Markets
512.50K
0.02
-2.49
-49.20
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.11-0.0918.18
Q04 2020--0.81-
Q03 2020-0.12-0.118.33
Q02 2020--0.12-
Q01 2020-0.13-0.130.00
Q02 2019-0.23-0.1343.48
Q03 2018--0.30-
Q01 2018--0.11-
Earnings Per EndEstimateRevision %Trend
4/2021 QR-0.1115.38Positive
7/2021 QR-0.1121.43Positive
10/2021 FY-0.4220.75Positive
10/2022 FY-0.5016.67Positive
Next Report Date-
Estimated EPS Next Report-0.11
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume61.60K
Shares Outstanding29.95M
Trades Count836
Dollar Volume1.83M
Avg. Volume459.74K
Avg. Weekly Volume113.30K
Avg. Monthly Volume118.39K
Avg. Quarterly Volume420.84K

Anixa Biosciences Inc. (NASDAQ: ANIX) stock closed at 4.23 per share at the end of the most recent trading day (a 1.93% change compared to the prior day closing price) with a volume of 61.60K shares and market capitalization of 126.69M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 4 people. Anixa Biosciences Inc. CEO is Amit Kumar.

The one-year performance of Anixa Biosciences Inc. stock is 90.5%, while year-to-date (YTD) performance is 37.79%. ANIX stock has a five-year performance of %. Its 52-week range is between 1.7 and 8.09, which gives ANIX stock a 52-week price range ratio of 39.59%

Anixa Biosciences Inc. currently has a PE ratio of -10.40, a price-to-book (PB) ratio of 9.87, a price-to-sale (PS) ratio of 242.52, a price to cashflow ratio of 18.90, a PEG ratio of 2.32, a ROA of -90.26%, a ROC of -100.90% and a ROE of -98.53%. The company’s profit margin is -%, its EBITDA margin is -1 854.50%, and its revenue ttm is $512.50 Thousand , which makes it $0.02 revenue per share.

Of the last four earnings reports from Anixa Biosciences Inc., there were 2 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.11 for the next earnings report. Anixa Biosciences Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Anixa Biosciences Inc. is Strong Buy (1), with a target price of $9.5, which is +124.59% compared to the current price. The earnings rating for Anixa Biosciences Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Anixa Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Anixa Biosciences Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 20.65, ATR14 : 0.30, CCI20 : 48.73, Chaikin Money Flow : -0.02, MACD : -0.01, Money Flow Index : 63.07, ROC : 6.28, RSI : 51.98, STOCH (14,3) : 44.09, STOCH RSI : 0.43, UO : 44.99, Williams %R : -55.91), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Anixa Biosciences Inc. in the last 12-months were: Amit Kumar (Buy at a value of $120 680), Arnold Baskies (Buy at a value of $87 100), Emily Gottschalk (Buy at a value of $121 028), Lewis H. Titterton (Buy at a value of $515 380)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Anixa Biosciences Inc.

Anixa Biosciences Inc, a cancer-focused biotechnology company, is engaged in harnessing the body's immune system in the fight against cancer. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for early detection of solid tumours which is based on the body's immune response to the presence of a malignancy. The company is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs that genetically engineer patient's own immune cells to fight cancer.

CEO: Amit Kumar

Telephone: +1 408 708-9808

Address: 3150 Almaden Expressway, San Jose 95118, CA, US

Number of employees: 4

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

65%35%

Bearish Bullish

53%47%

News

Stocktwits